Clinical trial
An Open-label, Phase I, Dose-escalation Study of ABR-217620 in Combination With Docetaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT00132379 is registered in ClinicalTrials.gov with Active Biotech AB as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Phase I, Dose-escalation Study of ABR-217620 in Combination With Docetaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
- Lead sponsor
- Active Biotech AB
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- November 30, 2005
- Completion date
- December 31, 2006
- Enrollment
- 13 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.